[go: up one dir, main page]

PT2925324T - Trans-4-{2-[4-(2,3-diclorofenil)-piperazin-1-il]-etil}-n,n-dimetilcarbamoíl-ciclo-hexilamina para tratar sintomas negativos primários de esquizofrenia - Google Patents

Trans-4-{2-[4-(2,3-diclorofenil)-piperazin-1-il]-etil}-n,n-dimetilcarbamoíl-ciclo-hexilamina para tratar sintomas negativos primários de esquizofrenia

Info

Publication number
PT2925324T
PT2925324T PT138055975T PT13805597T PT2925324T PT 2925324 T PT2925324 T PT 2925324T PT 138055975 T PT138055975 T PT 138055975T PT 13805597 T PT13805597 T PT 13805597T PT 2925324 T PT2925324 T PT 2925324T
Authority
PT
Portugal
Prior art keywords
dimethylcarbamoyl
cyclohexylamine
piperazin
schizophrenia
dichlorophenyl
Prior art date
Application number
PT138055975T
Other languages
English (en)
Original Assignee
Richter Gedeon Nyrt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=70289034&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT2925324(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Richter Gedeon Nyrt filed Critical Richter Gedeon Nyrt
Publication of PT2925324T publication Critical patent/PT2925324T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PT138055975T 2012-11-29 2013-11-28 Trans-4-{2-[4-(2,3-diclorofenil)-piperazin-1-il]-etil}-n,n-dimetilcarbamoíl-ciclo-hexilamina para tratar sintomas negativos primários de esquizofrenia PT2925324T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
HU1200691A HU231227B1 (hu) 2012-11-29 2012-11-29 Transz-4-{2-[4-(2,3-diklórfenil)-piperazin-1-il]-etil}N,N-dimetilkarbamoil-ciklohexilamin skizofrénia negatív tüneteinek kezelésére

Publications (1)

Publication Number Publication Date
PT2925324T true PT2925324T (pt) 2021-02-16

Family

ID=70289034

Family Applications (1)

Application Number Title Priority Date Filing Date
PT138055975T PT2925324T (pt) 2012-11-29 2013-11-28 Trans-4-{2-[4-(2,3-diclorofenil)-piperazin-1-il]-etil}-n,n-dimetilcarbamoíl-ciclo-hexilamina para tratar sintomas negativos primários de esquizofrenia

Country Status (36)

Country Link
US (1) US20150306094A1 (pt)
EP (2) EP2925324B1 (pt)
JP (2) JP2016501215A (pt)
KR (2) KR102314248B1 (pt)
CN (1) CN104812390A (pt)
AP (1) AP2015008448A0 (pt)
AU (1) AU2013350819B9 (pt)
BR (1) BR112015012512A2 (pt)
CA (1) CA2890952A1 (pt)
CL (1) CL2015001468A1 (pt)
CR (1) CR20150244A (pt)
CY (1) CY1123766T1 (pt)
DK (1) DK2925324T3 (pt)
EA (1) EA039245B1 (pt)
ES (1) ES2863052T3 (pt)
GE (1) GEP20186849B (pt)
HR (1) HRP20210486T1 (pt)
HU (2) HU231227B1 (pt)
IL (1) IL238723B (pt)
LT (1) LT2925324T (pt)
MD (2) MD4865C1 (pt)
MX (2) MX380506B (pt)
MY (1) MY174663A (pt)
NI (1) NI201500074A (pt)
NZ (1) NZ708295A (pt)
PE (1) PE20151052A1 (pt)
PH (1) PH12015501124A1 (pt)
PL (1) PL2925324T3 (pt)
PT (1) PT2925324T (pt)
RS (1) RS61509B1 (pt)
SG (1) SG11201503672SA (pt)
SI (1) SI2925324T1 (pt)
SM (1) SMT202100149T1 (pt)
UA (1) UA123492C2 (pt)
WO (1) WO2014083522A1 (pt)
ZA (1) ZA201503660B (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101612146B1 (ko) 2008-07-16 2016-04-12 리히터 게데온 닐트. 도파민 수용체 리간드를 함유하는 약학적 제형
CN105218484B (zh) * 2015-09-14 2018-02-23 安徽省逸欣铭医药科技有限公司 酒石酸卡利拉嗪及其制备方法和医药用途
HU231173B1 (hu) * 2016-07-08 2021-06-28 Richter Gedeon Nyrt. Ipari eljárás cariprazine előállítására
US11274087B2 (en) 2016-07-08 2022-03-15 Richter Gedeon Nyrt. Industrial process for the preparation of cariprazine
WO2019016828A1 (en) * 2017-07-15 2019-01-24 Msn Laboratories Private Limited, R&D Center NOVEL PROCESSES FOR THE PREPARATION OF TRANS-N- {4- [2- [4- (2,3-DICHLOROPHENYL) PIPERAZIN-1-YL] ETHYL] CYCLOHEXYL} -N ', N'-DIMETHYLUMED HYDROCHLORIDE AND POLYMORPHS THIS ONE
US20200375983A1 (en) * 2017-12-01 2020-12-03 Aurobindo Pharma Ltd A process for the preparation of cariprazine hydrochloride
WO2020056929A1 (zh) * 2018-09-21 2020-03-26 上海诚妙医药科技有限公司 卡利拉嗪盐酸盐的新晶型及其制备方法及其用途
US11547707B2 (en) 2019-04-10 2023-01-10 Richter Gedeon Nyrt. Carbamoyl cyclohexane derivatives for treating autism spectrum disorder
US11344503B2 (en) 2019-12-13 2022-05-31 Halo Science LLC Cariprazine release formulations

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU227534B1 (en) 2003-08-04 2011-08-29 Richter Gedeon Nyrt (thio)carbamoyl-cyclohexane derivatives, process for producing them and pharmaceutical compositions containing them
HU230748B1 (hu) 2007-05-11 2018-02-28 Richter Gedeon Nyrt Új piperazin só és előállítási eljárása
KR20100022955A (ko) * 2007-05-24 2010-03-03 리히터 게데온 닐트. (티오) -카르바모일-시클로헥산 유도체 및 정신분열 치료 방법
HUP0700369A2 (en) * 2007-05-24 2009-04-28 Richter Gedeon Nyrt Use of (thio)-carbamoyl-cyclohexane derivatives in the manufacture of a medicament for the treatment in the manufacture of a medicament for the treatment of schizophrenia
WO2010126527A1 (en) * 2009-05-01 2010-11-04 Forest Laboratories Holdings Limited Methods of treating cns disorders

Also Published As

Publication number Publication date
LT2925324T (lt) 2021-02-25
EP2925324A1 (en) 2015-10-07
PH12015501124B1 (en) 2015-08-03
AU2013350819B2 (en) 2018-05-31
WO2014083522A1 (en) 2014-06-05
JP2019163240A (ja) 2019-09-26
KR20150088270A (ko) 2015-07-31
EA201500575A1 (ru) 2015-09-30
EA039245B1 (ru) 2021-12-22
EP2925324B1 (en) 2020-12-30
HUE054054T2 (hu) 2021-08-30
EP3653211A1 (en) 2020-05-20
MY174663A (en) 2020-05-05
HRP20210486T1 (hr) 2021-05-14
UA123492C2 (uk) 2021-04-14
RS61509B1 (sr) 2021-03-31
CL2015001468A1 (es) 2015-08-07
NI201500074A (es) 2015-09-18
HUP1200691A1 (pt) 2014-06-30
PH12015501124A1 (en) 2015-08-03
MD4865C1 (ro) 2024-02-29
AU2013350819A1 (en) 2015-06-04
MD4865B1 (ro) 2023-07-31
NZ708295A (en) 2020-03-27
IL238723A0 (en) 2015-06-30
HU231227B1 (hu) 2022-03-28
PE20151052A1 (es) 2015-08-09
ZA201503660B (en) 2016-03-30
GEP20186849B (en) 2018-05-10
SG11201503672SA (en) 2015-06-29
MD20150058A2 (ro) 2015-11-30
AU2013350819B9 (en) 2018-06-21
DK2925324T3 (da) 2021-03-01
CY1123766T1 (el) 2022-05-27
CR20150244A (es) 2015-06-23
IL238723B (en) 2020-02-27
MX2021000342A (es) 2021-04-13
CN104812390A (zh) 2015-07-29
US20150306094A1 (en) 2015-10-29
MX380506B (es) 2025-03-04
KR102314248B1 (ko) 2021-10-19
MD20200089A2 (ro) 2021-05-31
JP2016501215A (ja) 2016-01-18
PL2925324T3 (pl) 2021-06-28
ES2863052T3 (es) 2021-10-08
BR112015012512A2 (pt) 2017-07-11
SI2925324T1 (sl) 2021-04-30
AP2015008448A0 (en) 2015-05-31
KR20210010955A (ko) 2021-01-28
SMT202100149T1 (it) 2021-07-12
HK1212608A1 (en) 2016-06-17
CA2890952A1 (en) 2014-06-05
MX2015006677A (es) 2015-08-10

Similar Documents

Publication Publication Date Title
IL238723A0 (en) trans-4-{2-[4-(3,2-dichlorophenyl)-piperazine-1-yl]-ethyl}-n,n-dimethylcarbamoyl-cyclohexylamine for the treatment of negative symptoms of schizophrenia
CO7000771A2 (es) Proceso para la fabricación de 1-[2-(2,4-dimetilsulfanil)fenil]piperazina
CY1119105T1 (el) Παραγωγα διπυραζολιου ως αναστολεις jak
EA201401054A1 (ru) N-циклиламиды в качестве нематоцидов
PL2981520T3 (pl) Nowy sposób syntezy 1-(2-((2,4-dimetylofenylo)tio)fenylo)piperazyny
AU2013369288A8 (en) Sulphate salts of N-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1H-benzo[d]imidazol-2-amine, preparation thereof and use of the same
PL2608789T5 (pl) Terapeutyczne zastosowania 1-[2-(2,4- dimetylofenylosulfanylo)- fenylo]piperazyny
IL238829B (en) Process for the preparation of 4-(cyclopropylmethoxy-3,5)-n-(dichloro-1-oxido-4-pyridyl)-5-methoxypyridine-2-carboxamide
PT2800746T (pt) Processo para o fabrico de 1-[2-(2,4-dimetilfenilsulfanil)- fenil]-piperazina
TH148741A (th) สารประกอบที่ถูกแทนที่ด้วยฮาโลเจนชนิดใหม่